03:14:23 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2020-11-10 Kvartalsrapport 2020-Q3
2020-08-12 Kvartalsrapport 2020-Q2
2020-05-13 Kvartalsrapport 2020-Q1
2020-04-29 Årsstämma 2020
2020-03-31 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-08 Kvartalsrapport 2019-Q2
2019-05-06 Kvartalsrapport 2019-Q1
2019-04-04 Ordinarie utdelning VELO 0.00 DKK
2019-04-03 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-13 Kvartalsrapport 2018-Q2
2018-05-14 Kvartalsrapport 2018-Q1
2018-04-16 Ordinarie utdelning VELO 0.00 DKK
2018-04-13 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-11-14 Kvartalsrapport 2017-Q3
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-16 Kvartalsrapport 2017-Q1
2017-04-10 Ordinarie utdelning VELO 0.00 DKK
2017-04-07 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-07-26 Extra Bolagsstämma 2016
2016-05-18 Kvartalsrapport 2016-Q1
2016-04-07 Ordinarie utdelning VELO 0.00 DKK
2016-04-06 Årsstämma 2016
2016-03-09 Bokslutskommuniké 2015
2015-11-11 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-20 Kvartalsrapport 2015-Q1
2015-03-27 Ordinarie utdelning VELO 0.00 DKK
2015-03-26 Årsstämma 2015
2015-03-03 Bokslutskommuniké 2014
2014-04-10 Ordinarie utdelning VELO 0.00 DKK
2013-04-18 Ordinarie utdelning VELO 0.00 DKK
2013-04-17 Årsstämma 2013
2012-04-19 Ordinarie utdelning VELO 0.00 DKK
2011-04-13 Ordinarie utdelning
2010-04-22 Ordinarie utdelning

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Veloxis Pharmaceuticals är ett läkemedelsbolag. Särskild specialisering återfinns inom behandlingen av organavstötning vid organtransplantationer. Visionen är att erbjuda läkemedel som underlättar absorptionen av läkemedel som fås oralt vid ingreppet. Bolaget innehar verksamhet på global nivå, främst inom Europa och Nordamerika. Veloxis Pharmaceuticals grundades 2002 och har sitt huvudkontor i Köpenhamn.
2019-03-12 17:59:47

Company Release no. 03/2019

To: NASDAQ Copenhagen A/S                                            

Copenhagen, Denmark, 12 March 2019

Notice to Convene Annual General Meeting 2019


The board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 ("the Company"), hereby convenes the annual general meeting in the Company which will be held on


Wednesday 3 April 2019 at 9 a.m. CET


at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, 1560 Copenhagen, Denmark.


Agenda

1                   Report by the Company's board of directors on the Company's activities during the past financial year

2                   Presentation of the audited annual report for approval
            
3                   Resolution on covering of losses as per the approved annual report

4                   Election of members to the board of directors

5                   Election of auditor

6                   Approval of fee to the board of directors for the financial year 2019

7                   Proposal by the board of directors on authorization to the board of directors to issue warrants and amendment of the articles of association in accordance therewith
             
8                   Proposal by the board of directors for approval of updated remuneration policy including general guidelines for incentive-based remuneration to members of the board of directors and executive management and amendment of the articles of association in accordance therewith

9                   Proposal from the board of directors to authorize the board of directors to increase the share capital at market price by cash payment with up to nominally DKK 17,181,953.50 with or without pre-emptive subscription rights for the shareholders, including the proposal for amendment of the Company's articles of association in accordance therewith

10                 Proposal by the board of directors on authorization to the Company to acquire own shares

11                 Proposal by the board of directors on authorization to the chairman of the annual general meeting, with a right of substitution, to file the resolutions passed at the general meeting for registration with the Danish Business Authority


Please see attached document for complete proposals.




Attachment